皮肌炎市場：按類型、治療類型、分銷渠道、地區 - 規模、份額、展望、機會分析，2022-2030 年

皮肌炎是一種罕見的肌肉發炎疾病。表現為對稱性近端肌無力、皮疹、食管功能障礙、間質性肺病等宏觀症狀。皮肌炎與惡性腫瘤密切相關，尤其是在成人中。皮肌炎是一種全身性疾病，最常影響皮膚和肌肉，但也會影響關節、食道、肺和心臟（較少見）。皮肌炎表現為特徵性皮膚表現和對稱性近端骨骼肌無力。它還會影響其他器官系統，例如肺、心血管系統和消化系統。皮肌炎是由多種因素引起的，包括遺傳因素、免疫因素、感染性疾病、藥物以及輻射等環境因素。

皮肌炎分為成人皮肌炎、肌源性皮肌炎和幼年型皮肌炎三種類型。)分為三種皮肌炎。皮肌炎肌炎是一個術語，用於描述具有皮肌炎皮膚病學特徵但無相關肌肉表現的患者。幼年（小兒）皮肌炎（JDMS）是皮肌炎（DM）的一種早發形式，是一種累及血管的全身性自身免疫性炎症性肌病，其特徵是近端和對稱性肌肉無力、覺醒時以皮膚損害和全身症狀為特徵。

市場動態

市場參與者參與了皮肌炎新療法的開發，預計這將在預測期內推動市場增長。例如，2022 年 5 月，臨床階段生物技術公司 Kezar Life Sciences, Inc. 宣布了 zetomipzomib (KZR-616) 在皮肌炎 (DM) 和多發性肌炎 (PM) 患者中的 PRESIDIO 2 期臨床試驗。試驗結果。 PRESIDIO 試驗的結果顯示，大多數 DM 和 PM 患者的總改善評分（TIS）都有臨床意義的改善。

研究的主要特徵

• 本報告深入分析了以 2021 年為基準年的預測期 (2022-2030) 的全球皮肌炎市場、市場規模和復合年增長率 (CAGR%)。
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供關鍵見解，例如市場驅動因素和製約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略。
• 根據公司亮點、按類型劃分的投資組合、主要亮點、財務業績和市場戰略等參數，介紹全球皮肌炎市場主要參與者的概況。
• 本研究涵蓋的主要公司包括 AstraZeneca Plc.、Bristol-Myers Squibb Company、Octapharma AG、Corbus Pharmaceuticals Holdings, Inc.、CSL Limited、Ermium Therapeutics、Kezar Life Sciences Inc.、Mallinckrodt Plc.、Neovacs、 Horizo□□n Therapeutics plc.和輝瑞公司。
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
• 《全球皮肌炎市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球皮肌炎市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按類型分類
  • 市場概況：按治療類型分類
  • 市場概況：按銷售渠道
  • 市場概況：按地區
  • 市場機會地圖

第 3 章全球皮肌炎市場洞察

• 司機
• 約束因素
• 市場機會
• 影響分析
• 管道分析
• 害蟲分析
• 波特的五力分析
• 主要發展狀況
• 監管情景
• 保險報銷場景
• 合併/收購場景
• 品牌映射

第 4 章全球皮肌炎市場：冠狀病毒 (COVID-19) 大流行的影響

• OVID-19 的流行病學
• 對供需的影響
• 對臨床試驗的影響

第 5 章全球皮肌炎市場類型，2017-2030

• 成人皮肌炎
• 皮肌炎肌炎
• 幼年（兒科）皮肌炎 (JDMS)

第 6 章全球皮肌炎市場：按治療類型分類，2017-2030

• 抗炎藥
• 免疫抑製劑
• 免疫球蛋白
• 其他（血漿置換、單克隆抗體等）

第 7 章。全球皮肌炎市場：按分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 8 章全球皮肌炎市場：按地區劃分，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 德國
• 英國
• 法國
• 意大利
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 澳大利亞
• 韓國
• 東盟
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 南非
• 中非
• 北非

第九章公司簡介

• 阿斯利康公司
  • 公司亮點
  • 產品組合
  • 主要亮點
  • 財務業績
  • 市場策略
• 百時美施貴寶公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• Octapharma 公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• Corvus Pharmaceuticals Holdings Inc.
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• CSL 有限公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• 鉺療法
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• 凱撒生命科學有限公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• 馬林克羅特公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• 新後衛
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• Horizo□□n Therapeutics plc.
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 效果趨勢
  • 市場策略
• 輝瑞日本公司
  • 公司簡介
  • 產品組合
  • 主要亮點
  • 財務業績
  • 市場策略

第 10 章

• 調查方法
• 關於出版商

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study:

• This report provides an in-depth analysis of the global dermatomyositis market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dermatomyositis market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Neovacs, Horizon Therapeutics plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Detailed Segmentation:

• Global Dermatomyositis Market, By Type:
  • Adult Dermatomyositis
  • Dermatomyositis Sine Myositis
  • Juvenile (Childhood) Dermatomyositis (JDMS)
• Global Dermatomyositis Market, By Treatment Type:
  • Anti-inflammatory Medication
  • Immunosuppressive Drugs
  • Immunoglobulin
  • Others (Plasma Exchange, Monoclonal antibody among others)
• Global Dermatomyositis Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Dermatomyositis Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AstraZeneca Plc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
  • Octapharma AG
  • Corbus Pharmaceuticals Holdings, Inc.
  • CSL Limited
  • Ermium Therapeutics
  • Kezar Life Sciences Inc.
  • Mallinckrodt Plc.
  • Neovacs, Horizon Therapeutics plc.
  • Pfizer Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Global Dermatomyositis Market Insights

• Drivers
• Restraints
• Opportunity
• Impact Analysis
• Pipeline Analysis
• PEST Analysis
• Porter's Five Forces Analysis
• Key Developments
• Regulatory Scenario
• Reimbursement Scenario
• Merger & Acquisition Scenario
• Brand Mapping

4. Global Dermatomyositis Market - Impact of Coronavirus (Covid-19) Pandemic

• OVID-19 Epidemiology
• Impact On Supply And Demand
• Impact on Clinical Trials

5. Global Dermatomyositis Market, By Type, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Adult Dermatomyositis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Dermatomyositis Sine Myositis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Juvenile (Childhood) Dermatomyositis (JDMS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

6. Global Dermatomyositis Market, By Treatment Type, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Anti-inflammatory Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Immunosuppressive Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Immunoglobulin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Plasma Exchange, Monoclonal antibody among others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

7. Global Dermatomyositis Market, By Distribution Channel, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

8. Global Dermatomyositis Market, By Region, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Region at Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2030, (US$ Million)
• South Africa
• Central Africa
• North Africa

9. Company Profiles

• AstraZeneca Plc.*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Octapharma AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Corbus Pharmaceuticals Holdings, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ermium Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kezar Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mallinckrodt Plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Neovacs
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Horizon Therapeutics plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About us